Evidence map›Paper›PMID 42826365›Full record

Trial reportJCO precision oncology2026

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With

Maria Vieito, Elena Garralda Cabanas, Inderjit Mehmi, Caroline Gaudy-Marqueste, Bert H O'Neil, Theresa M Medina, Amy L Body, Ana Arance, Shivaani Kummar, Yana G Najjar and 7 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria VieitoHospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-7531-343X
Elena Garralda CabanasHospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-4412-7842
Inderjit MehmiThe Angeles Clinic & Research Institute, Inc, Los Angeles, CA.ORCID 0000-0002-2253-2206
Caroline Gaudy-MarquesteDermatology and Skin Cancer Department, Aix Marseille Univ, APHM, CRCM Inserm, U1068, CNRS, UMR7258, UM105, CEPCM, CHU Timone, Marseille, France.
Bert H O'NeilCommunity MD Anderson Cancer Center-North, Indianapolis, IN.
Theresa M MedinaUCHealth University of Colorado Hospital, Aurora, CO.ORCID 0000-0003-0579-4121
Amy L BodyMonash Medical Centre, Melbourne, VIC, Australia.ORCID 0000-0002-0601-8485
Ana AranceHospital Clinic Barcelona and IDIBAPS, Barcelona, Spain.
Shivaani KummarKnight Cancer Institute, Oregon Health and Science University, Portland, OR.ORCID 0000-0001-6906-1627
Yana G NajjarUPMC Hillman Cancer Center, Pittsburgh, PA.ORCID 0000-0002-0138-1664
Philippe L BedardPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6771-2999
Andrew RankinDay One Biopharmaceuticals, Inc, Brisbane, CA.
Caroline ChuDay One Biopharmaceuticals, Inc, Brisbane, CA.ORCID 0009-0006-7428-7851
Chris McKennaDay One Biopharmaceuticals, Inc, Brisbane, CA.
Stephanie HumeDay One Biopharmaceuticals, Inc, Brisbane, CA.ORCID 0000-0002-8448-8917
Lisa M KoppDay One Biopharmaceuticals, Inc, Brisbane, CA.
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-4911-6165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTovorafenib is an oral, selective, CNS-penetrant, type II inhibitor of BRAF and CRAF. PATIENTS AND

methodsPatients ≥12 years of age with a recurrent/refractory solid tumor with a

resultsTwenty-three patients were enrolled; eight in the melanoma cohort and 15 in the tumor-agnostic cohort. The median age was 53 years (range, 21-71), and 57% of patients had ≥2 lines of prior therapy. Fourteen patients had tumors with

conclusionTovorafenib demonstrated single-agent clinical activity in solid tumors with

Indexed as

MelanomaPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-rafAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalBRAF protein, humanPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-rafRaf1 protein, human

Identifiers

PMID42826365
PMCPMC13657394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.